{"type":"trials","record":{"id":28338,"source_id":"clinicaltrials-gov","external_id":"NCT07816289","title":"Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)","brief_summary":"This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).","overall_status":"Not Yet Recruiting","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Ollin Biosciences, Inc.","enrollment":400,"countries":[],"start_date":"2026-10-15","completion_date":"2029-12-15","last_update_date":"2026-09-11","source_url":"https://clinicaltrials.gov/study/NCT07816289","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T00:17:13.08831+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"SAHARA","age_range":"50 Years","comparator":"Ranibizumab","organization":"Ollin Biosciences, Inc.","interventions":["OLN324","Ranibizumab"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in BCVA — Day 1 to Week 36","Mean change in OCT CST — Day 1 to Week 12","Change in PED thickness — Day 1 to Week 12","Percentage of participants without retinal fluid in the central subfield at Week 12 — Week 12"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Wet Age-related Macular Degeneration","OLN324","Ranibizumab"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07816289","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-10-15 to 2029-12-15","comparator":"Ranibizumab","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.799Z","intervention":["OLN324","Ranibizumab"],"participants":400,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in BCVA — Day 1 to Week 36","Mean change in OCT CST — Day 1 to Week 12","Change in PED thickness — Day 1 to Week 12","Percentage of participants without retinal fluid in the central subfield at Week 12 — Week 12"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/28338","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}